Literature DB >> 16707589

Erlotinib: optimizing therapy with predictors of response?

Susan Goodin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707589     DOI: 10.1158/1078-0432.CCR-06-0426

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  6 in total

1.  Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.

Authors:  Gary M Clark
Journal:  Mol Oncol       Date:  2007-12-08       Impact factor: 6.603

2.  Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Authors:  Malabika Sen; Sonali Joyce; Mary Panahandeh; Changyou Li; Sufi M Thomas; Jessica Maxwell; Lin Wang; William E Gooding; Daniel E Johnson; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

Review 3.  Acquired resistance to drugs targeting receptor tyrosine kinases.

Authors:  Steven A Rosenzweig
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

Review 4.  Acquired Resistance to Drugs Targeting Tyrosine Kinases.

Authors:  Steven A Rosenzweig
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

5.  Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

Authors:  Andrew N Hughes; Mary E R O'Brien; W Jeffrey Petty; Jonathan B Chick; Elaine Rankin; Penella J Woll; David Dunlop; Marianne Nicolson; Ramesh Boinpally; Julie Wolf; Allan Price
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

6.  Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis.

Authors:  Minyan Zeng; Qi Feng; Ming Lu; Jun Zhou; Zuyao Yang; Jinling Tang
Journal:  Onco Targets Ther       Date:  2018-10-08       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.